Recombinant Alexa Fluor® 568 Anti-Dysferlin antibody [JAI-1-49-3] (ab313017)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Alexa Fluor® 568 Rabbit monoclonal [JAI-1-49-3] to Dysferlin
- Suitable for: Target binding affinity, Antibody labelling
- Conjugation: Alexa Fluor® 568. Ex: 578nm, Em: 603nm
Related conjugates and formulations
Overview
-
Product name
Alexa Fluor® 568 Anti-Dysferlin antibody [JAI-1-49-3]
See all Dysferlin primary antibodies -
Description
Alexa Fluor® 568 Rabbit monoclonal [JAI-1-49-3] to Dysferlin -
Host species
Rabbit -
Conjugation
Alexa Fluor® 568. Ex: 578nm, Em: 603nm -
Tested applications
Suitable for: Target binding affinity, Antibody labellingmore details -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
General notes
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for Abtrial: learn more here.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 30% Glycerol (glycerin, glycerine), 1% BSA, 68% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
JAI-1-49-3 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab313017 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Target binding affinity |
Use at an assay dependent concentration.
|
|
Antibody labelling |
Use at an assay dependent concentration.
|
Notes |
---|
Target binding affinity
Use at an assay dependent concentration. |
Antibody labelling
Use at an assay dependent concentration. |
Target
-
Function
Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress. -
Tissue specificity
Expressed in skeletal muscle, myoblast, myotube and in the syncytiotrophoblast (STB) of the placenta (at protein level). Highly expressed in skeletal muscle. Also found in heart, brain, spleen, intestine, placenta and at lower levels in liver, lung, kidney and pancreas. -
Involvement in disease
Defects in DYSF are the cause of limb-girdle muscular dystrophy type 2B (LGMD2B) [MIM:253601]. LGMD2B is an autosomal recessive degenerative myopathy characterized by weakness and atrophy starting in the proximal pelvifemoral muscles, with onset in the late teens or later, massive elevation of serum creatine kinase levels and slow progression. Scapular muscle involvement is minor and not present at onset. Upper limb girdle involvement follows some years after the onset in lower limbs.
Defects in DYSF are the cause of Miyoshi muscular dystrophy type (MMD1) [MIM:254130]. MMD1 is a late-onset muscular dystrophy involving the distal lower limb musculature. It is characterized by weakness that initially affects the gastrocnemius muscle during early adulthood. Otherwise the phenotype overlaps with LGMD2B, especially in age at onset and creatine kinase elevation.
Defects in DYSF are the cause of distal myopathy with anterior tibial onset (DMAT) [MIM:606768]. Onset of the disorder is between 14 and 28 years of age and the anterior tibial muscles are the first muscle group to be involved. Inheritance is autosomal recessive. -
Sequence similarities
Belongs to the ferlin family.
Contains 5 C2 domains. -
Developmental stage
Expression in limb tissue from 5-6 weeks embryos; persists throughout development. -
Domain
The C2 domain 1 associates with lipid membranes in a calcium-dependent manner. -
Cellular localization
Cell membrane > sarcolemma. Cytoplasmic vesicle membrane. Colocalizes, during muscle differentiation, with BIN1 in the T-tubule system of myotubules and at the site of contact between two myotubes or a myoblast and a myotube. Wounding of myotubes led to its focal enrichment to the site of injury and to its relocalization in a Ca(2+)-dependent manner toward the plasma membrane. Colocalizes with AHNAK, AHNAK2 and PARVB at the sarcolemma of skeletal muscle. Detected on the apical plasma membrane of the syncytiotrophoblast. Reaches the plasmma membrane through a caveolin-independent mechanism. Retained by caveolin at the plasmma membrane (By similarity). Colocalizes, during muscle differentiation, with CACNA1S in the T-tubule system of myotubules (By similarity). Accumulates and colocalizes with fusion vesicles at the sarcolemma disruption sites. - Information by UniProt
-
Alternative names
- DMAT antibody
- DYSF antibody
- DYSF_HUMAN antibody
see all
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab313017 has not yet been referenced specifically in any publications.